218 related articles for article (PubMed ID: 37985446)
1. Association of TOP2A and ADH1B with lipid levels and prognosis in patients with lung adenocarcinoma and squamous cell carcinoma.
Yin D; Zhang Y; Li H; Cheng L
Clin Respir J; 2023 Dec; 17(12):1301-1315. PubMed ID: 37985446
[TBL] [Abstract][Full Text] [Related]
2. System analysis of
Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
[TBL] [Abstract][Full Text] [Related]
3. Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients.
Ding Y; Zhang L; Guo L; Wu C; Zhou J; Zhou Y; Ma J; Li X; Ji P; Wang M; Zhu W; Shi C; Li S; Wu W; Zhu W; Xiao D; Fu C; He Q; Sun R; Mao X; Lizaso A; Li B; Han-Zhang H; Zhang Z
Thorac Cancer; 2020 Jan; 11(1):103-112. PubMed ID: 31692283
[TBL] [Abstract][Full Text] [Related]
4. [Identification of differentially expressed genes between lung adenocarcinoma and squamous cell carcinoma using transcriber signature analysis].
Peng S; Li X; Liu Q; Zhang Y; Zou L; Gong X; Wang M; Ma X
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jun; 39(6):641-649. PubMed ID: 31270041
[TBL] [Abstract][Full Text] [Related]
5. Blood FOLR3 methylation dysregulations and heterogeneity in non-small lung cancer highlight its strong associations with lung squamous carcinoma.
Qu Y; Zhang X; Qiao R; Di F; Song Y; Wang J; Ji L; Zhang J; Gu W; Fang Y; Han B; Yang R; Dai L; Ouyang S
Respir Res; 2024 Jan; 25(1):59. PubMed ID: 38273401
[TBL] [Abstract][Full Text] [Related]
6. Bioinformatics analysis of differentially expressed miRNAs in non-small cell lung cancer.
Yu H; Pang Z; Li G; Gu T
J Clin Lab Anal; 2021 Feb; 35(2):e23588. PubMed ID: 32965722
[TBL] [Abstract][Full Text] [Related]
7. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Li Y; Zheng P; Zhan X
Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
[TBL] [Abstract][Full Text] [Related]
8. GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma.
Ning J; Jiang S; Li X; Wang Y; Deng X; Zhang Z; He L; Wang D; Jiang Y
BMC Pulm Med; 2021 Jun; 21(1):199. PubMed ID: 34112123
[TBL] [Abstract][Full Text] [Related]
9. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
Yang K; Wu Y
BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
[TBL] [Abstract][Full Text] [Related]
11. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
Hou G; Lu Z; Bi Y; Deng J; Yang X
Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
[TBL] [Abstract][Full Text] [Related]
12. Expression of the Topoisomerase II Alpha (TOP2A) Gene in Lung Adenocarcinoma Cells and the Association with Patient Outcomes.
Du X; Xue Z; Lv J; Wang H
Med Sci Monit; 2020 Dec; 26():e929120. PubMed ID: 33361736
[TBL] [Abstract][Full Text] [Related]
13. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
Meng F; Zhang L; Ren Y; Ma Q
J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
[TBL] [Abstract][Full Text] [Related]
14. Elevated expression of Twinfilin-1 is correlated with inferior prognosis of lung adenocarcinoma.
Kaishang Z; Xue P; Shaozhong Z; Yingying F; Yan Z; Chanjun S; Zhenzhen L; Xiangnan L
Life Sci; 2018 Dec; 215():159-169. PubMed ID: 30391462
[TBL] [Abstract][Full Text] [Related]
15. Elevated TOP2A and UBE2C expressions correlate with poor prognosis in patients with surgically resected lung adenocarcinoma: a study based on immunohistochemical analysis and bioinformatics.
Guo W; Sun S; Guo L; Song P; Xue X; Zhang H; Zhang G; Wang Z; Qiu B; Tan F; Xue Q; Gao Y; Gao S; He J
J Cancer Res Clin Oncol; 2020 Apr; 146(4):821-841. PubMed ID: 32103339
[TBL] [Abstract][Full Text] [Related]
16. What's the difference between lung adenocarcinoma and lung squamous cell carcinoma? Evidence from a retrospective analysis in a cohort of Chinese patients.
Wang W; Liu H; Li G
Front Endocrinol (Lausanne); 2022; 13():947443. PubMed ID: 36105402
[TBL] [Abstract][Full Text] [Related]
17. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
Xu XL; Gong Y; Zhao DP
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
[TBL] [Abstract][Full Text] [Related]
18. Smoking is Associated with Lung Adenocarcinoma and Lung Squamous Cell Carcinoma Progression through Inducing Distinguishing lncRNA Alterations in Different Genders.
Liu B; Liu Y; Zou J; Zou M; Cheng Z
Anticancer Agents Med Chem; 2022; 22(8):1541-1550. PubMed ID: 34315392
[TBL] [Abstract][Full Text] [Related]
19. Common and distinct patterns of acquired uniparental disomy and homozygous deletions between lung squamous cell carcinomas and lung adenocarcinoma.
Tuna M; Mills GB; Amos CI
Neoplasia; 2023 Nov; 45():100932. PubMed ID: 37801862
[TBL] [Abstract][Full Text] [Related]
20. The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.
Fu L; Wang H; Wei D; Wang B; Zhang C; Zhu T; Ma Z; Li Z; Wu Y; Yu G
PLoS One; 2020; 15(5):e0233283. PubMed ID: 32437446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
